Pönisch, Wolfram <br/><br/>
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.  [electronic resource] 

 -  British journal of haematology  Jul 2013 
 - 202-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/bjh.12361  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bendamustine Hydrochloride<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Lenalidomide<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Nitrogen Mustard Compounds--administration & dosage<br/>Prednisolone--administration & dosage<br/>Recurrence<br/>Thalidomide--administration & dosage